LEVERAGE mRNA · Laboratory Evolution of Virus-likE pRotein cAGes for Eukaryotic mRNA delivery
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2019-05-01 → 2021-04-30
- Финансиране от ЕС
- 191 149 €
- Участници
- 1
- Схема
- MSCA-IF-EF-ST
Линиите свързват координатора с партньорите.
Накратко на български
Протеинови обвивки от бактерията Aquifex aeolicus се модифицират в лаборатория, за да пренасят генетична информация (mRNA) в клетките, подобно на вирусите. Това помага за разработването на по-ефективни методи за генна терапия при заболявания, причинени от мутирали или липсващи гени.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Laboratory Evolution of Virus-likE pRotein cAGes for Eukaryotic mRNA delivery
Our genetic information is encoded in nucleic acid (NA) molecules. NAs are promising candidates for treating disease by stimulating, inhibiting, or replacing other NAs or proteins inside of eukaryotic cells—a process known as “gene therapy.” However, methods to deliver genes efficiently and safely into cells are still lacking. One way to transport NAs into cells is by packaging them into a hollow container made of proteins, a method that has been successfully hijacked by viruses for a long time. Because viruses are experts at selectively packaging and delivering their genomes across membranes, recreating these processes in the lab might provide inspiration on how to design better NA delivery vessels for biomedical applications. If successful, many genetically linked diseases that are caused by mutated or missing genes could become curable. The protein cage I chose to study as a possible NA delivery vehicle originates from the cage-forming bacterial protein lumazine synthase found in Aquifex aeolicus (AaLS). AaLS consists of 60 identical subunits and assembles into symmetrical, porous shells. The cage functions as a cellular nanoreactor and catalyzes the penultimate step of riboflavin biosynthesis. AaLS has no affinity for NAs. Protein engineering and directed evolution were used to alter AaLS’s packaging preferences and make it package its own ribonucleic acid (RNA) genome. After four rounds of evolution, a new AaLS variant called NC-4 emerged. This variant exhibited a 240-subunit, T=4 structure consisting of interlaced trimeric units that bears a striking resemblance to some natural viral capsids. With this exciting result in hand, my main objectives were to evaluate the RNA packaging properties of the four protein cage generations and utilize this knowledge to expand the cages’ ability to package other RNAs. Specifically, I asked (1) what RNAs and how much of them were packaged in the evolved NC-4 nucleocapsid, (2) how the RNAs were packaged into the protein cages in bacteria and in vitro, and (3) if NC-4 could encapsulate other non-native NAs. The successful conversion of a bacterial enzyme into a nucleocapsid that efficiently packages and protects its own encoding mRNA opens up exciting new research avenues in the area of protein engineering and drug delivery. Directed evolution is a powerful tool not only for optimizing binding or enzyme activity, but also for recreating more complex biological processes in the lab. Although work is still ongoing, the major milestones of the outlined objectives have been fulfilled, some of which have already been published as further described below.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Nucleic acids are promising candidates for treating disease by stimulating, inhibiting, or replacing other nucleic acids or proteins inside of eukaryotic cells—a process known as “gene therapy.” However, methods to efficiently and safely deliver genes into cells are still lacking. The problem is that nucleic acids are not cell permeant and degrade before reaching the cytosol. One way to transport oligonucleotides into cells is by packaging them into hollow containers made of proteins, a method that has been successfully hijacked by viruses for a long time.Here, we propose to design and engineer an artificial proteinaceous container that (1) selectively encapsulates ribonucleic acids (RNAs) using a known RNA recognition tag and (2) delivers this RNA into the cytosol of mammalian cells. Protein engineering, which embodies both rational design and computational modeling, will be used to create the starting design of this artificial protein container. The initial design will be based on the protein lumazine synthase from the bacterial organism Aquifex aeolicus (AaLS), which forms small but highly symmetrical nanocompartments in bacteria and is very tolerant to genetic changes. To optimize this design, we will use directed evolution to induce an artificial selection pressure on a large population of distinct capsid variants, allowing us to obtain only the best-performing capsid variants: those that can enter and disassemble selectively inside of mammalian cells, thereby releasing the enclosed RNA molecules into the cytosol. New AaLS containers will be thoroughly characterized using cutting-edge technologies, such next-generation sequencing and cryo-electron microscopy.The ultimate goal of LEVERAGE mRNA is to use the designed and evolved capsids to deliver messenger RNAs (mRNAs) into cells that encode missing or dysfunctional proteins, for example in enzyme replacement therapies. If successful, this action will have lasting positive impacts on human health.
Оригинален текст от CORDIS (на английски).
Участници
- EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH · ZuerichКоординаторШвейцария
Връзки
Данни: CORDIS, © Европейски съюз
